HC Wainwright Reaffirms “Buy” Rating for Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $17.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Curis’ Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.24) EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $17.00.

Curis Price Performance

NASDAQ CRIS opened at $0.77 on Friday. The business’s fifty day moving average is $0.98 and its 200-day moving average is $1.25. The stock has a market capitalization of $10.59 million, a price-to-earnings ratio of -0.65 and a beta of 3.02. Curis has a one year low of $0.75 and a one year high of $3.13.

Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Thursday, March 19th. The biotechnology company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The company had revenue of $1.14 million for the quarter, compared to the consensus estimate of $3.25 million. Research analysts expect that Curis will post -7.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC boosted its holdings in shares of Curis by 46.2% in the fourth quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 27,343 shares during the period. CM Management LLC raised its stake in Curis by 47.7% in the third quarter. CM Management LLC now owns 325,000 shares of the biotechnology company’s stock valued at $540,000 after purchasing an additional 105,000 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Curis during the 4th quarter valued at $26,000. Renaissance Technologies LLC lifted its stake in Curis by 37.3% during the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock worth $238,000 after purchasing an additional 65,404 shares during the last quarter. Finally, Armistice Capital LLC lifted its position in Curis by 8.7% in the 3rd quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock worth $1,624,000 after buying an additional 78,265 shares during the last quarter. 29.97% of the stock is owned by institutional investors.

Key Headlines Impacting Curis

Here are the key news stories impacting Curis this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating with a $17.00 price target — a highly bullish analyst endorsement that can attract speculative buying given the large upside to the current price. Benzinga
• Positive Sentiment: Company and management continue to advance oncology programs: Curis is targeting full enrollment in its PCNSL registrational study within 12–18 months and is progressing a CLL proof‑of‑concept — milestones that would materially de‑risk and re‑rate the pipeline if achieved. Seeking Alpha
• Neutral Sentiment: Curis issued a fourth-quarter 2025 business update and hosted a conference call — useful for detail and guidance but neutral until management gives clear forward guidance or cash/runway updates. PR Newswire
• Neutral Sentiment: Multiple transcripts of the Q4 2025 earnings call are available (MSN/Yahoo/Seeking Alpha) for investors who want management color; transcripts themselves don’t change fundamentals but help interpret pipeline timelines. MSN Transcript
• Negative Sentiment: Q4 results missed expectations — EPS of ($0.50) missed consensus by $0.07 and revenue of $1.14M missed estimates (~$3.25M). The miss raises near‑term financing and execution risk for a small‑cap biotech with limited revenue. MarketBeat Earnings
• Negative Sentiment: Curis reported an update indicating a pause in the emavusertib trial for certain indications (AML/MDS) — any trial pause increases clinical risk and could delay value realization from that program. Investors should watch for details on reasons for the pause and the path to restart. TipRanks
• Neutral Sentiment: Short‑interest notices in the data feed show anomalous/zero values and NaN changes — current published short interest figures do not present a reliable signal. Monitor official exchange short‑interest reports for clarity.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.